Abstract
Thirteen patients with herpesvirus infections who were unresponsive to at least 72 h of intermittent acyclovir administration received high-dose continuous infusion. Steady-state concentrations were maintained at between 20 and 98 mumol/liter. Of 12 patients who had continuous infusion for greater than 5 days, 7 (58%) resolved their infections, as determined by clinical and virologic parameters, suggesting that continuous infusion may succeed in some patients who do not respond to conventional therapy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bean B., Fletcher C., Englund J., Lehrman S. N., Ellis M. N. Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. Diagn Microbiol Infect Dis. 1987 Jul;7(3):199–204. doi: 10.1016/0732-8893(87)90005-8. [DOI] [PubMed] [Google Scholar]
- Blum M. R., Liao S. H., de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982 Jul 20;73(1A):186–192. doi: 10.1016/0002-9343(82)90088-2. [DOI] [PubMed] [Google Scholar]
- Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
- D'Argenio D. Z., Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979 Mar;9(2):115–134. doi: 10.1016/0010-468x(79)90025-4. [DOI] [PubMed] [Google Scholar]
- Dekker C., Ellis M. N., McLaren C., Hunter G., Rogers J., Barry D. W. Virus resistance in clinical practice. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):137–152. doi: 10.1093/jac/12.suppl_b.137. [DOI] [PubMed] [Google Scholar]
- Erice A., Jordan M. C., Chace B. A., Fletcher C., Chinnock B. J., Balfour H. H., Jr Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA. 1987 Jun 12;257(22):3082–3087. [PubMed] [Google Scholar]
- Feldman S., Robertson P. K., Lott L., Thornton D. Neurotoxicity due to adenine arabinoside therapy during varicella-zoster virus infections in immunocompromised children. J Infect Dis. 1986 Nov;154(5):889–893. doi: 10.1093/infdis/154.5.889. [DOI] [PubMed] [Google Scholar]
- Hanto D. W., Frizzera G., Gajl-Peczalska K. J., Sakamoto K., Purtilo D. T., Balfour H. H., Jr, Simmons R. L., Najarian J. S. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. 1982 Apr 15;306(15):913–918. doi: 10.1056/NEJM198204153061506. [DOI] [PubMed] [Google Scholar]
- Norris S. A., Kessler H. A., Fife K. H. Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis. 1988 Jan;157(1):209–210. doi: 10.1093/infdis/157.1.209. [DOI] [PubMed] [Google Scholar]
- Quinn R. P., de Miranda P., Gerald L., Good S. S. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. doi: 10.1016/0003-2697(79)90148-9. [DOI] [PubMed] [Google Scholar]
- Spector S. A., Hintz M., Wyborny C., Connor J. D., Keeney R. E., Liao S. Treatment of herpes virus infections in immunocompromised patients with acyclovir by continuous intravenous infusion. Am J Med. 1982 Jul 20;73(1A):275–280. doi: 10.1016/0002-9343(82)90105-x. [DOI] [PubMed] [Google Scholar]